GeneDx’s (WGS) Sell (D) Rating Reiterated at Weiss Ratings

Weiss Ratings reissued their sell (d) rating on shares of GeneDx (NASDAQ:WGS) in a research report sent to investors on Friday morning,Weiss Ratings reports.

Several other analysts also recently weighed in on the company. Wells Fargo & Company upped their price objective on GeneDx from $78.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 30th. Piper Sandler increased their target price on shares of GeneDx from $120.00 to $140.00 and gave the stock an “overweight” rating in a report on Thursday, September 11th. BTIG Research lifted their price target on shares of GeneDx from $125.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, October 22nd. Canaccord Genuity Group set a $155.00 price objective on shares of GeneDx and gave the company a “buy” rating in a research note on Monday, October 20th. Finally, Guggenheim restated a “buy” rating and issued a $115.00 target price (up previously from $88.00) on shares of GeneDx in a research report on Monday, June 30th. Eight analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, GeneDx has an average rating of “Moderate Buy” and a consensus target price of $112.80.

GeneDx Stock Performance

NASDAQ WGS opened at $128.87 on Friday. The firm’s 50 day simple moving average is $123.22 and its 200 day simple moving average is $97.73. The firm has a market capitalization of $3.70 billion, a price-to-earnings ratio of 2,577.40 and a beta of 1.98. The company has a current ratio of 2.87, a quick ratio of 2.70 and a debt-to-equity ratio of 0.19. GeneDx has a 1 year low of $55.17 and a 1 year high of $136.00.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.10 by $0.40. The business had revenue of $102.69 million during the quarter, compared to the consensus estimate of $86.00 million. GeneDx had a net margin of 0.39% and a return on equity of 16.51%. GeneDx has set its FY 2025 guidance at EPS. As a group, research analysts expect that GeneDx will post 0.97 earnings per share for the current fiscal year.

Insider Buying and Selling at GeneDx

In other news, CFO Kevin Feeley sold 3,728 shares of GeneDx stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $121.47, for a total transaction of $452,840.16. Following the transaction, the chief financial officer owned 8,755 shares in the company, valued at approximately $1,063,469.85. The trade was a 29.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jason Ryan sold 38,072 shares of the business’s stock in a transaction on Wednesday, August 27th. The stock was sold at an average price of $127.30, for a total transaction of $4,846,565.60. Following the completion of the sale, the director directly owned 103,284 shares in the company, valued at approximately $13,148,053.20. This represents a 26.93% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 556,371 shares of company stock valued at $67,489,314 in the last quarter. 29.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. acquired a new stake in shares of GeneDx in the first quarter valued at about $44,614,000. William Blair Investment Management LLC boosted its holdings in GeneDx by 37.2% in the second quarter. William Blair Investment Management LLC now owns 1,631,402 shares of the company’s stock valued at $150,595,000 after acquiring an additional 442,414 shares during the last quarter. Alliancebernstein L.P. boosted its holdings in GeneDx by 3,054.5% in the first quarter. Alliancebernstein L.P. now owns 436,900 shares of the company’s stock valued at $38,694,000 after acquiring an additional 423,050 shares during the last quarter. Jennison Associates LLC increased its position in GeneDx by 6,163.1% during the 2nd quarter. Jennison Associates LLC now owns 397,896 shares of the company’s stock valued at $36,730,000 after purchasing an additional 391,543 shares during the period. Finally, Westfield Capital Management Co. LP raised its holdings in GeneDx by 164.8% during the 2nd quarter. Westfield Capital Management Co. LP now owns 589,188 shares of the company’s stock worth $54,388,000 after purchasing an additional 366,711 shares during the last quarter. 61.72% of the stock is owned by institutional investors and hedge funds.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.